KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sabra Health Care REIT (SBRA) Cash from Financing Activities (2016 - 2025)

Sabra Health Care REIT (SBRA) has 15 years of Cash from Financing Activities data on record, last reported at -$100.9 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities changed 0.07% year-over-year to -$100.9 million; the TTM value through Dec 2025 reached $40.8 million, up 122.45%, while the annual FY2025 figure was $40.8 million, 122.45% up from the prior year.
  • Cash from Financing Activities reached -$100.9 million in Q4 2025 per SBRA's latest filing, down from $206.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $371.6 million in Q3 2021 and bottomed at -$274.6 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is -$34.1 million, with a median of -$57.4 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 2164.31% in 2022, then tumbled 978.33% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$274.6 million in 2021, then soared by 95.08% to -$13.5 million in 2022, then soared by 30.74% to -$9.4 million in 2023, then crashed by 978.33% to -$101.0 million in 2024, then grew by 0.07% to -$100.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$100.9 million in Q4 2025, $206.2 million in Q3 2025, and $36.7 million in Q2 2025.